Literature DB >> 25774503

STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.

Cuiqi Zhou, Yonghui Jiao, Renzhi Wang, Song-Guang Ren, Kolja Wawrowsky, Shlomo Melmed.   

Abstract

Pituitary somatotroph adenomas result in dysregulated growth hormone (GH) hypersecretion and acromegaly; however, regulatory mechanisms that promote GH hypersecretion remain elusive. Here, we provide evidence that STAT3 directly induces somatotroph tumor cell GH. Evaluation of pituitary tumors revealed that STAT3 expression was enhanced in human GH-secreting adenomas compared with that in nonsecreting pituitary tumors. Moreover, STAT3 and GH expression were concordant in a somatotroph adenoma tissue array. Promoter and expression analysis in a GH-secreting rat cell line (GH3) revealed that STAT3 specifically binds the Gh promoter and induces transcription. Stable expression of STAT3 in GH3 cells induced expression of endogenous GH, and expression of a constitutively active STAT3 further enhanced GH production. Conversely, expression of dominant-negative STAT3 abrogated GH expression. In primary human somatotroph adenoma-derived cell cultures, STAT3 suppression with the specific inhibitor S3I-201 attenuated GH transcription and reduced GH secretion in the majority of derivative cultures. In addition, S3I-201 attenuated somatotroph tumor growth and GH secretion in a rat xenograft model. GH induced STAT3 phosphorylation and nuclear translocation, indicating a positive feedback loop between STAT3 and GH in somatotroph tumor cells. Together, these results indicate that adenoma GH hypersecretion is the result of STAT3-dependent GH induction, which in turn promotes STAT3 expression, and suggest STAT3 as a potential therapeutic target for pituitary somatotroph adenomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25774503      PMCID: PMC4396466          DOI: 10.1172/JCI78173

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

Review 1.  gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways.

Authors:  E Arzt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.

Authors:  J Turkson; D Ryan; J S Kim; Y Zhang; Z Chen; E Haura; A Laudano; S Sebti; A D Hamilton; R Jove
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

Review 4.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

Review 5.  The role of STAT proteins in growth hormone signaling.

Authors:  J Herrington; L S Smit; J Schwartz; C Carter-Su
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

6.  Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.

Authors:  J Kreutzer; M L Vance; M B Lopes; E R Laws
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

7.  Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients.

Authors:  I Shimon; Z R Cohen; Z Ram; M Hadani
Journal:  Neurosurgery       Date:  2001-06       Impact factor: 4.654

Review 8.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

9.  Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions.

Authors:  Vanessa Mynard; Laurence Guignat; Jocelyne Devin-Leclerc; Xavier Bertagna; Maria Grazia Catelli
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

10.  Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.

Authors:  Robert M Starke; Daniel M S Raper; Spencer C Payne; Mary L Vance; Edward H Oldfield; John A Jane
Journal:  J Clin Endocrinol Metab       Date:  2013-06-04       Impact factor: 5.958

View more
  21 in total

Review 1.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 2.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

3.  Humanin inhibits apoptosis in pituitary tumor cells through several signaling pathways including NF-κB activation.

Authors:  María Florencia Gottardo; Mariela Moreno Ayala; Jimena Ferraris; Sandra Zárate; Daniel Pisera; Marianela Candolfi; Gabriela Jaita; Adriana Seilicovich
Journal:  J Cell Commun Signal       Date:  2017-04-04       Impact factor: 5.782

4.  Excess growth hormone suppresses DNA damage repair in epithelial cells.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert Barrett; Hiraku Kameda; Kolja Wawrowsky; Anat Ben-Shlomo; Masaaki Yamamoto; John Gleeson; Catherine Bresee; Vera Gorbunova; Shlomo Melmed
Journal:  JCI Insight       Date:  2019-02-07

5.  Identification of Transcriptional Metabolic Dysregulation in Subtypes of Pituitary Adenoma by Integrated Bioinformatics Analysis.

Authors:  Jintao Hu; Huachun Yin; Bo Li; Hui Yang
Journal:  Diabetes Metab Syndr Obes       Date:  2019-11-27       Impact factor: 3.168

6.  Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches.

Authors:  Biao Li; Xiaowei Wang; Chenguang Yang; Siqi Wen; Jiajia Li; Na Li; Ying Long; Yun Mu; Jianping Liu; Qin Liu; Xuejun Li; Dominic M Desiderio; Xianquan Zhan
Journal:  EPMA J       Date:  2021-03-03       Impact factor: 6.543

7.  Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma.

Authors:  Indre Valiulyte; Giedrius Steponaitis; Daina Skiriute; Arimantas Tamasauskas; Paulina Vaitkiene
Journal:  BMC Med Genet       Date:  2017-07-14       Impact factor: 2.103

8.  Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.

Authors:  Jiayin An; Xiangdong Pei; Zhenle Zang; Zheng Zhou; Jintao Hu; Xin Zheng; Yin Zhang; Jiaojiang He; Lian Duan; Rufei Shen; Weihua Zhang; Feng Zhu; Song Li; Hui Yang
Journal:  Oncotarget       Date:  2017-06-06

9.  Correlation between the Expression of Interleukin-6, STAT3, E-Cadherin and N-Cadherin Protein and Invasiveness in Nonfunctional Pituitary Adenomas.

Authors:  Xiaoxu Shen; Qi Liu; Jian Xu; Yang Wang
Journal:  J Neurol Surg B Skull Base       Date:  2019-12-05

10.  In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

Authors:  Thomas Cuny; Caroline Zeiller; Martin Bidlingmaier; Céline Défilles; Catherine Roche; Marie-Pierre Blanchard; Marily Theodoropoulou; Thomas Graillon; Morgane Pertuit; Dominique Figarella-Branger; Alain Enjalbert; Thierry Brue; Anne Barlier
Journal:  Endocr Relat Cancer       Date:  2016-06-07       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.